VINC Vincerx Pharma Inc

USD 5.06 -1.00 -16.50165
Icon

Vincerx Pharma Inc (VINC) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 5.06

-1.00 (-16.50)%

USD 0.12B

0.60M

N/A

USD 5.50 (+8.70%)

Icon

VINC

Vincerx Pharma Inc (USD)
COMMON STOCK | NSD
USD 5.06
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.12B

USD 5.50 (+8.70%)

USD 5.06

Vincerx Pharma Inc (VINC) Stock Forecast

N/A

Based on the Vincerx Pharma Inc stock forecast from 0 analysts, the average analyst target price for Vincerx Pharma Inc is not available over the next 12 months. Vincerx Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Vincerx Pharma Inc is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Vincerx Pharma Inc’s stock price was USD 5.06. Vincerx Pharma Inc’s stock price has changed by -7.16% over the past week, +33.16% over the past month and +432.63% over the last year.

No recent analyst target price found for Vincerx Pharma Inc
No recent average analyst rating found for Vincerx Pharma Inc

Company Overview Vincerx Pharma Inc

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical tri...Read More

https://vincerx.com

260 Sheridan Avenue, Palo Alto, CA, United States, 94306

41

December

USD

USA

Adjusted Closing Price for Vincerx Pharma Inc (VINC)

Loading...

Unadjusted Closing Price for Vincerx Pharma Inc (VINC)

Loading...

Share Trading Volume for Vincerx Pharma Inc Shares

Loading...

Compare Performance of Vincerx Pharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for VINC

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Vincerx Pharma Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing VINC

Symbol Name VINC's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Vincerx Pharma Inc (VINC) Stock

Stock Target Advisor's fundamental analysis for Vincerx Pharma Inc's stock is Very Bearish.

Unfortunately we do not have enough data on VINC's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on VINC's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on VINC's stock to indicate if its overvalued.

The last closing price of VINC's stock was USD 5.06.

The most recent market capitalization for VINC is USD 0.12B.

Unfortunately we do not have enough analyst data on VINC's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Vincerx Pharma Inc's stock.

As per our most recent records Vincerx Pharma Inc has 41 Employees.

Vincerx Pharma Inc's registered address is 260 Sheridan Avenue, Palo Alto, CA, United States, 94306. You can get more information about it from Vincerx Pharma Inc's website at https://vincerx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...